Anupam Rasayan India Limited has informed the Exchange about Transcript

Anupam Rasayan reported FY26 revenue of INR 2,384 crores, up 65% YoY, with EBITDA of INR 543 crores (23% margin) and PAT of INR 222 crores (9% margin). The company delivered operating cash flow of INR 334 crores. Revenue mix improved with agrochemicals now at 55% (down from 76% in FY22), while pharma grew 15x to 20% and performance materials tripled to 18%. Management announced acquiring 43.3%-48.2% stake in Bliss GVS Pharma (INR 927 crores revenue) via INR 300 crores NCD and quasi-equity funding, expected to be EPS accretive. Pro forma consolidated revenue across all entities (Anupam, Tanfac, Jayhawk, Bliss) would be over INR 4,000 crores with EBITDA of ~INR 834 crores. The order book stands at INR 14,000 crores. Peak standalone revenue potential from current INR 2,500 crores gross block is INR 3,500 crores. No major capex planned; maintenance capex expected at INR 50-75 crores annually.